Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study
Journal of Clinical Medicine · 12.04.2026 · 15 (8) · 2932
DOI: 10.3390/jcm15082932 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.04.2026. Verfasst von Eva Cervilla-Muñoz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Venous Thromboembolism Unit, Internal Medicine Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The role of systemic fibrinolysis in patients with intermediate-risk pulmonary embolism (PE) remains controversial because of the uncertain balance between potential benefits and bleeding risk. This study evaluated the association between systemic fibrinolysis and clinical outcomes in a real-world cohort of patients with symptomatic intermediate-risk PE.
Methods
This prospective observational study included consecutive patients with symptomatic intermediate-risk PE from 2009 to 2019 at a tertiary hospital. Patients receiving systemic fibrinolysis were compared with those treated with anticoagulation alone. The primary outcome was 30-day all-cause mortality. Secondary outcomes included major bleeding, and recurrent venous thromboembolism. Multivariable Cox proportional hazards regression models were used to adjust for potential confounders.
Results
A total of 560 patients with symptomatic intermediate-risk PE were included, of whom 54 (9.6%) received systemic fibrinolysis. Patients receiving fibrinolysis were younger than those treated with anticoagulation alone (median age 58 vs. 73 years; p < 0.001). Thirty-day mortality occurred in 1.8% and 3.3% of patients, respectively (p = 1). After adjustment, fibrinolysis was not associated with reduced 30-day mortality (aHR 1.5; 95% CI 0.1–17.9), nor with a significant increase in 30-day major bleeding (aHR 2.6; 95% CI 0.8–8.3). Intracranial hemorrhage and VTE recurrences were rare.
Conclusions
In this real-world cohort, systemic fibrinolysis was not associated with improved survival compared with anticoagulation alone, consistent with current guideline recommendations against routine fibrinolysis in intermediate-risk PE.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Venous Thromboembolism Unit, Internal Medicine Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
- School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.
- Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.
- Department of Cardiology, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.
ORCID-Profile: Pablo Demelo-Rodríguez, Rubén Alonso-Beato, Lucía Ordieres-Ortega, Marina López-Rubio
Zitieren
APA
Cervilla-Muñoz, E., Demelo-Rodríguez, P., Alonso-Beato, R., Juárez-Fernández, M., Sousa-Casasnovas, I., Ordieres-Ortega, L., López-Rubio, M., Alvarez-Sala Walther, L. A., & Galeano-Valle, F. (2026). Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study. Journal of Clinical Medicine, 15(8), 2932. https://doi.org/10.3390/jcm15082932
Vancouver
Cervilla-Muñoz E, Demelo-Rodríguez P, Alonso-Beato R, Juárez-Fernández M, Sousa-Casasnovas I, Ordieres-Ortega L, et al. Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study. Journal of Clinical Medicine. 2026;15(8):2932. doi:10.3390/jcm15082932
BibTeX
@article{CervillaMuoz2026,
author = {Cervilla-Muñoz, Eva and Demelo-Rodríguez, Pablo and Alonso-Beato, Rubén and Juárez-Fernández, Miriam and Sousa-Casasnovas, Iago and Ordieres-Ortega, Lucía and López-Rubio, Marina and Alvarez-Sala Walther, Luis-Antonio and Galeano-Valle, Francisco},
title = {Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {8},
pages = {2932},
doi = {10.3390/jcm15082932}
}
EUVIMED